Alice C Levine, MD
img_Alice C Levine
PROFESSOR | Medicine, Endocrinology, Diabetes and Bone Disease
ASSOCIATE PROFESSOR | Oncological Sciences
Are you a patient?
Endocrine, Diabetes and Bone Diseases (Endocrinology), Internal Medicine
Interactive roles of androgens and growth factors in human prostate development and neoplasia

Interactive roles of androgens and growth factors in human prostate development and neoplasia

Dr. Levine’s Research Laboratory focuses on understanding how hormones and growth factors coordinately regulate prostate growth in order to develop new treatment strategies for men with prostatic disorders.  Co-directed by Dr. Alexander Kirschenbaum, Clinical Associate Professor of Urology, her group was the first to publish on the successful management of benign prostatic hyperplasia with hormonal therapy.  They also reported that androgens increase stromal cell growth in the prostate and also regulate the powerful angiogenic factor, vascular endothelial cell growth factor (VEGF).  Dr. Levine’s group were also among the first to determine the cell-specific expression of cyclooxygenase-2 (COX-2) in the human prostate and to report that selective COX-2 inhibitors kill prostate cancer cells in vitro and in vivo.  They established the role of COX-2 in hypoxia mediated upregulation of survival and angiogenic proteins in human prostate cancer cells.  Dr. Levine’s group recently isolated and characterized a protein derived from dietary bitter melon seeds that selectively kills pre-neoplastic and neoplastic prostate cancer cells.  Her group has also published extensively on the mechanisms underlying prostate cancer bone metastases and developed a bone-targeting compound aimed at preventing and treating prostate cancer bone metastases.

MD, Columbia University College of Physicians & Surgeons

Internship, Internal Medicine, Fletcher Allen Health Care-MCHV Campus

Residency, Internal Medicine, Fletcher Allen Health Care-MCHV Campus

Fellowship, Endocrinology, Diabetes and Metabolism, Mount Sinai Hospital


American Board of Internal Medicine
Adrenal Hypercortisolism: Controversies in Diagnosis, Prognosis and Treatment

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Levine during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • HRA Pharma

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.